Drugline is a fortnightly electronic drug bulletin for health professionals.


Drugline is a fortnightly electronic drug bulletin providing information on new medicines, new developments, current affairs, new indications, new PBS listings and deletions and general issues of importance to all health professionals. Click below to view the most recent volumes of Drugline.

Reversing the Anticoagulant Effects of Factor Xa Inhibitors

Drugline Volume 486

Andexanet alfa has provisional approval for the reversal of anticoagulation in adult patients who experience life-threatening or uncontrolled bleeding with a direct factor Xa inhibitor (apixaban or rivaroxaban). Andexanet alfa is a recombinant form…

Read more

Trastuzumab Deruxtecan on the PBS

Drugline Volume 485

Trastuzumab deruxtecan has been added to the Pharmaceutical Benefits Scheme (PBS) for the treatment of metastatic human epidermal growth factor receptor 2 (HER2)–positive breast cancer. Around 15-20% of all breast cancers are HER2 positive,…

Read more

Baclofen Safety Update

Drugline Volume 484

The Therapeutic Goods Administration (TGA) has published a safety alert regarding the use of high doses of baclofen. This alert has been issued following recent coronial inquiries into two deaths. Baclofen is a skeletal…

Read more

Oral Azacitidine on the PBS

Drugline Volume 483

Azacitidine tablets are now available on the Pharmaceutical Benefits Scheme (PBS) for the treatment of acute myeloid leukaemia (AML) following intensive induction chemotherapy. The safety and efficacy of azacitidine tablets in this setting was…

Read more

Enzalutamide for Metastatic Hormone-Sensitive Prostate Cancer

Drugline Volume 482

The Pharmaceutical Benefits Scheme (PBS) listing for enzalutamide has recently been expanded. Enzalutamide is an oral inhibitor of androgen receptor signalling. It is now subsidised for the treatment of metastatic hormone-sensitive prostate cancer, in…

Read more

Darolutamide and Liver Test Abnormalities

Drugline Volume 481

The darolutamide product information has recently been updated to include information about hepatotoxicity. Darolutamide is a non-steroidal androgen receptor antagonist used in the treatment of prostate cancer. In the ARAMIS trial involving 1508 men…

Read more
Load More

November 2023

February 2023

September 2022

August 2022

April 2022

February 2022

December 2021

November 2021

October 2021

August 2021

Post-injection Syndrome (Aug. 20 2021)

Alirocumab on the PBS (Aug. 06 2021)

May 2021

April 2021

PBS Changes for Adalimumab (Apr. 30 2021)

Short-course Oxycodone (Apr. 16 2021)

March 2021

January 2021

December 2020

November 2020

October 2020

September 2020

July 2020

May 2020

March 2020

December 2019

November 2019

October 2019

New Warning for Febuxostat (Oct. 18 2019)

Naloxone Nasal Spray (Oct. 04 2019)

April 2019

New High-Strength Insulin (Apr. 18 2019)

Tofacitinib Safety Issue (Apr. 05 2019)

March 2019

February 2019

January 2019

December 2018